Form 4: Altimmune CSO Increases Stake Through RSU Vesting, ESPP

Altimmune's Chief Scientific Officer, M. Scot Roberts, increased his beneficial ownership of common stock through the vesting of Restricted Stock Units and participation in the Employee Stock Purchase Plan.

Summary

• M. Scot Roberts, Chief Scientific Officer of Altimmune, Inc. (ALT), reported multiple transactions involving the company's common stock.
• On January 30, 2026, Roberts acquired 9,275 shares through RSU vesting and simultaneously disposed of 2,859 shares at $5.60 per share to cover tax obligations, resulting in 101,811 shares beneficially owned.
• On January 31, 2026, Roberts purchased 5,567 shares at $3.07 per share through the company's 2019 Employee Stock Purchase Plan (ESPP), bringing his total beneficial ownership to 107,378 shares.
• On February 2, 2026, Roberts acquired an additional 7,775 shares from RSU vesting and disposed of 2,329 shares at $5.55 per share for tax purposes, increasing his beneficial ownership to 112,824 shares.
• The ESPP shares were acquired at 85% of the closing price on August 1, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the Chief Scientific Officer is increasing his beneficial ownership through both earned compensation and a voluntary purchase plan, indicating continued commitment to the company.

Positives

• Chief Scientific Officer M. Scot Roberts increased his direct beneficial ownership of Altimmune common stock from 104,670 shares (before the first reported transaction) to 112,824 shares.
• Acquisition of 5,567 shares through the Employee Stock Purchase Plan (ESPP) at a discounted price of $3.07 per share, indicating management's continued investment in the company.
• Vesting of 9,275 and 7,775 Restricted Stock Units (RSUs) represents earned compensation and continued long-term incentive alignment.

Negatives

• Disposal of 2,859 shares at $5.60 and 2,329 shares at $5.55 to cover tax obligations associated with RSU vesting, which is a common practice but reduces direct share count.

Future Outlook

The vesting schedules for the Restricted Stock Units indicate continued long-term incentive alignment for the Chief Scientific Officer, with vesting occurring in substantially equal annual installments over four years from their respective grant dates (January 30, 2023, and February 2, 2022).

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions through vesting and employee stock purchase plans, generally reflect management's confidence in the company's long-term prospects. While this Form 4 is specific to an individual's compensation and investment, it aligns with typical executive compensation structures in the biotechnology sector, which often include equity incentives to align management interests with shareholder value.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of Restricted Stock Units (RSUs) and Employee Stock Purchase Plans (ESPPs) are standard compensation and incentive mechanisms across the biotechnology and broader corporate landscape.
• The RSU vesting schedule over four years is a common practice designed to promote long-term retention and performance, similar to programs seen at companies like Amgen or Gilead Sciences.
• The ESPP, allowing purchase at a discount (85% of the closing price), is also a widely adopted benefit, comparable to those offered by many S&P 500 companies, encouraging broad employee ownership.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, signaling management's confidence.
• Employees: Participation in the ESPP and RSU vesting demonstrates the company's commitment to employee equity participation and long-term incentives.

Next Steps

• Continued vesting of remaining Restricted Stock Units in substantially equal annual installments over the next few years.

Key Dates

Recommendation

The filing details routine insider transactions, including RSU vesting and ESPP purchases, which are expected compensation events. While the increase in beneficial ownership by a key executive is a positive signal of confidence, these transactions alone do not provide new fundamental information to warrant a change in investment recommendation. Investors should consider these routine activities within the broader context of Altimmune's financial performance and strategic developments.

Keywords

Altimmune, ALT, Form 4, Insider Trading, M. Scot Roberts, Chief Scientific Officer, Restricted Stock Units, RSU, Employee Stock Purchase Plan, ESPP, Stock Vesting, Beneficial Ownership